Joseph Tintelnot, MD retweeted
Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot nature.com/articles/s41591-0…
Joseph Tintelnot, MD retweeted
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy brnw.ch/21wQHWu @JosephTintelnot @UKEHamburg @lab_binder
Joseph Tintelnot, MD retweeted
You are what you eat! Macrophages activate different gene expression (and functional) programs to IL-4 based on the type of apoptotic cell they ingested! Cool stuff by Bosurgi lab @ScienceMagazine science.org/doi/10.1126/scie…
Joseph Tintelnot, MD retweeted
In the latest issue! Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer dlvr.it/T4rrVY
Joseph Tintelnot, MD retweeted
Very cool - rejuvenation of the immune system! nature.com/articles/s41586-0…
Joseph Tintelnot, MD retweeted
In the latest issue! A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells dlvr.it/T3YJvS
Joseph Tintelnot, MD retweeted
Together with @IdoAmitLab we’re very excited to introduce BiCE (Bispecific DC-T Cell Engager)- a new platform to engineer immune cell communication for #cancer #immunotherapy. Led by the amazing @yuval_shap @orenbarboy, now out @CellCellPress: cell.com/fulltext/S0092-8674…
(1/11)
Joseph Tintelnot, MD retweeted
Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent immune response against a distant tumor. @yerinchen led the charge w/ help from @DjenetBousbaine, @VeinbachsA, @BelkaidLab. @ScienceMagazine 1/26
science.org/doi/10.1126/scie…
Joseph Tintelnot, MD retweeted
We made a short video to explain the findings of these papers to a lay audience. This was arguably harder than publishing the actual papers.
@uclcancer @uclmedsci @RadNetCRUKCoL
Very excited to share two papers published today in @CellCellPress describing stem cell plasticity in CRC. (1/22)
cell.com/cell/fulltext/S0092…
cell.com/cell/fulltext/S0092…
Joseph Tintelnot, MD retweeted
💥BIG PAPER ALERT💥 So excited to share our latest, out now @Nature! Here, we uncover a spatially confined interplay between subsets of IL-1b+ macrophages and tumor cells that fuels pathogenic inflammation in pancreatic cancer (1/n)
nature.com/articles/s41586-0…
Joseph Tintelnot, MD retweeted
#ScienceSaturday
While many of you have heard of the microbiome which describes the bacteria in our body, have you heard of the #mycobiome? This refers to the fungi that can be found in our gut as well as in tumors. In a recent report in @Cancer_Cell, investigators found that the fungus Aspergillus sydowii could be found in human lung adenocarcinomas and correlated with a worsened outcome. In experimental mouse models of lung cancer, this organism induced the tumor infiltration of myeloid derived suppressor cells (MDSC) which inhibited tumor reactive T cells. These findings may allow us to improve outcomes in cancer patients by targeting specific fungi.
Joseph Tintelnot, MD retweeted
Thrilled to see our #microbiome #immunology paper is out in @Nature!
We mapped T cell receptor specificity to the gut microbiome at the level of a single TCR versus a single strain.
nature.com/articles/s41586-0…
Here are highlights of our findings.
Joseph Tintelnot, MD retweeted
I think we need to talk about how devastating this cancer microbiome refutation paper from
@StevenSalzberg1
and colleagues is. It really speaks to how devoid of critical thinking and intellectual depth our glam publishing ecosystem has become. 1/n
biorxiv.org/content/10.1101/…
Joseph Tintelnot, MD retweeted
#ScienceSaturday CD8+ T cells classically kill tumor cells by recognition of peptide antigens in the context of class I MHC molecules, and downregulation or loss of class I expression can lead to tumor escape. @EmilyCLerner et al have now shown that CD8+ T cells can kill class I negative tumor cells through the receptor NKG2D, paving the way for strategies to neutralize this escape mechanism.
nature.com/articles/s43018-0…
Joseph Tintelnot, MD retweeted
Macrophages mess with ❤️ rhythm
⚡️
transcriptomics and protein data describe 3-fold expansion of these leukocytes in patients with atrial fibrillation. Among the top expressed genes: osteopontin (SPP1), catalyzing atrial fibrosis and inflammation
❤️🔥
science.org/doi/10.1126/scie…
Joseph Tintelnot, MD retweeted
Read our latest work on the power of CD4 T cells in cancer immunity:
nature.com/articles/s41586-0…
Joseph Tintelnot, MD retweeted
1. ENTER #mRNAvaccines for #pancreaticcancer! Long-term #PDAC survivor story PART3.
"Do #PDACs REALLY have vaccine neoantigens (NAs)"? (aren’t they lowly mutated?)
If each patient = own NAs, how do you vaccinate?
Maybe mRNA? But how?
@Nature nature.com/articles/s41586-0…
👇🏽 [1/32]
Joseph Tintelnot, MD retweeted
Excited to share our TRACERx nature publication on circulating tumor DNA (#ctDNA, #MRD) detection in resectable lung cancer led by @AbboshChris, @Afrankell, @juditkisistok, Thomas Harrison, Aaron Garnett, @nbirkbak and @NickyMcGranahan 👇👇👇 Tweetorial🧵
nature.com/articles/s41586-0…
Joseph Tintelnot, MD retweeted
Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵nature.com/articles/s41586-0…
Joseph Tintelnot, MD retweeted
I'm very excited to share that our work is online @Nature! We found that STING suppresses progression of dormant metastasis. Huge thanks to all the co-authors! @LabMassague @LoweLabMSKCC @SunLab_Official @dana_peer @KarunaMDPhD @ciacobu @MSKCancerCenter
nature.com/articles/s41586-0…























